New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
September 30, 2013
08:38 EDTBGMDBG Medicine announces preliminary decision by CMS on BGM Galectin-3 test
BG Medicine announced that the Centers for Medicare and Medicaid Services, or CMS, have made a preliminary decision to set the Medicare payment rate for the Company's BGM Galectin-3 test at the amount of a cross walked test whose 2013 national limitation amount is $30.24, subject to a final determination by CMS by year-end 2013. The new payment rate, if finalized, will replace the BGM Galectin-3 test's national limitation amount of $17.80 that was effective in 2013. This preliminary determination by CMS comes in response to BG Medicine's request for reconsideration of the 2013 CMS determination. The BGM Galectin-3 test is a novel test, which is cleared by the FDA as an aid in assessing the prognosis of patients with chronic heart failure.
News For BGMD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 31, 2015
08:45 EDTBGMDBG Medicine sees requiring additional capital in 'near future'
Paul Sohmer, CEO of BG Medicine, said: "FDA clearance of the first automated assay for galectin-3 represents a significant commercial milestone for BG Medicine. Our commercial strategy will increasingly rely on the success of our automated partners to commercialize automated testing for galectin-3. We anticipate that beginning in the second half of 2015 our growth in revenues will depend on the timing and extent to which our automated partners are successful in gaining adoption of their automated tests for galectin-3. Concurrently, we will continue to manage aggressively our operating expenses and cash burn. We also expect that we will require additional capital in the near future to continue our operations and grow our business."
07:18 EDTBGMDBG Medicine files Premarket Notification with FDA for BGM Galectin-3 Test
Subscribe for More Information
07:11 EDTBGMDBG Medicine reports Q4 EPS (4c), one estimate (5c)
Reports Q4 revenue $554,000, one estimate $800,000.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use